7,9-Didecyl-6,8-dimethyl-1,2,3,4-tetrahydroquinolizin-5-ium;2,2,2-trifluoroacetate | 1334291-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: 7,9-Didecyl-6,8-dimethyl-1,2,3,4-tetrahydroquinolizin-5-ium;2,2,2-trifluoroacetate
• CAS: 1334291-51-8
• 化学式: C₂F₃O₂*C₃₁H₅₆N
• 分子量: 555.808
• InChiKey: CCCKMVJJRKCGNO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  8.59
• 重原子数：
  39
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  44
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， -70.0~20.0 ℃ 、399.91 kPa 条件下， 反应 11.0h， 生成 7,9-Didecyl-6,8-dimethyl-1,2,3,4-tetrahydroquinolizin-5-ium;2,2,2-trifluoroacetate
  参考文献：
  名称：

  The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents

  摘要：

  Prostate cancer is a leading cause of death among males in the United States. As the chemokine receptor CCR5 is over-expressed in more aggressive forms of prostate cancer, and is also a critical receptor in inflammation, chemokine receptor CCR5 antagonists could potentially act as anti-prostate cancer agents. Anibamine, a natural product CCR5 antagonist, provides a unique molecular scaffold for the generation of novel analogs with possible anti-prostate cancer activity. A series of analogs of anibamine were designed, synthesized and tested against several prostate cancer cell lines. The analogs all acted as CCR5 antagonists at micromolar range affinity to the receptor while their anti-proliferative activity varied depending on the cell line type and their chemical structural properties. Further basal cytotoxicity characterization on these compounds indicated some of them may be suitable for in vivo studies. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.07.058

文献信息

• The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents
  作者：Kendra M. Haney、Feng Zhang、Christopher K. Arnatt、Yunyun Yuan、Guo Li、Joy L. Ware、David A. Gewirtz、Yan Zhang

  DOI：10.1016/j.bmcl.2011.07.058

  日期：2011.9

  Prostate cancer is a leading cause of death among males in the United States. As the chemokine receptor CCR5 is over-expressed in more aggressive forms of prostate cancer, and is also a critical receptor in inflammation, chemokine receptor CCR5 antagonists could potentially act as anti-prostate cancer agents. Anibamine, a natural product CCR5 antagonist, provides a unique molecular scaffold for the generation of novel analogs with possible anti-prostate cancer activity. A series of analogs of anibamine were designed, synthesized and tested against several prostate cancer cell lines. The analogs all acted as CCR5 antagonists at micromolar range affinity to the receptor while their anti-proliferative activity varied depending on the cell line type and their chemical structural properties. Further basal cytotoxicity characterization on these compounds indicated some of them may be suitable for in vivo studies. Published by Elsevier Ltd.